文献速递胸部肿瘤放疗

肿瘤纯度作为IIIA-N2期非小细胞肺癌术后放疗预后与预测生物标志物的转录组分析

Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-03-13

基于Lung ART-IFCT 0503试验的285例术后IIIA-N2期非小细胞肺癌转录组数据,用ESTIMATE算法推断肿瘤纯度(TP),分析其与总生存(OS)和无病生存(DFS)的关系。中位TP为0.64,高TP与更差的OS(48.5 vs 106.5个月,P<.001)和DFS(18.4 vs 48.0个月,P=.017)相关;TP与PORT存在交互作用(OS P=.049,DFS P=.07)。结论认为低TP独立关联更好预后,PORT可能在低TP肿瘤中更有效,但属探索性发现需独立验证。

要点

  • 高肿瘤纯度与更差的OS和DFS独立相关(中位OS 48.5 vs 106.5个月,P<.001)。
  • TP与术后放疗存在交互作用(OS P=.049,DFS P=.07),低TP肿瘤可能更受益于PORT。
  • TP与T细胞免疫浸润呈负相关(CD3⁺ r=-0.52;CD8⁺ r=-0.45)。

核心结论

  • TP反映增殖相关通路和肿瘤微环境特征,低TP独立关联切除后IIIA-N2期NSCLC的更好预后。
  • PORT可能在低TP肿瘤中更有效,但该发现为探索性,需独立验证。

研究设计与样本

  • 基于Lung ART-IFCT 0503试验的转录组分析,对285例样本成功行RNA测序。
  • 使用ESTIMATE算法推断TP,采用Kaplan-Meier和多变量Cox模型评估与OS和DFS的关联。
  • 285例切除后IIIA-N2期NSCLC患者中144例接受PORT,中位年龄61岁,31%为女性,80%为非鳞组织学。

主要发现

  • 中位TP为0.64(范围0.41-0.92),PORT组略高(0.65 vs 0.63;P=.006)。
  • TP与H&E病理学家估计的细胞密度相关(r=0.23,P<.001),鳞癌中更高(0.68 vs 0.63,P<.001),并随坏死增加(r=0.31,P<10-6)。
  • 转录组分析证实TP与增殖相关通路相关并伴缺氧特征减少(FDR<0.001)。
  • TP与免疫组化T细胞浸润呈负相关(CD3⁺ r=-0.52;CD8⁺ r=-0.45)。
  • 高TP与更差OS(48.5 vs 106.5个月,P<.001)和DFS(18.4 vs 48.0个月,P=.017)相关,TP×PORT交互作用OS P=.049、DFS P=.07。

临床怎么用

  • TP可作为切除后IIIA-N2期NSCLC的预后分层参考,低TP提示更好预后。
  • TP可能辅助筛选PORT获益人群,低TP肿瘤或更受益,但需独立验证后用于临床决策。

局限性

  • PORT获益预测为探索性发现,需独立验证。
  • TP通过ESTIMATE算法从转录组推断,非直接病理测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor purity (TP), the proportion of malignant cells within a tumor sample, is an important feature of the tumor microenvironment. Using transcriptomic data from the Lung ART-IFCT 0503 trial, we investigated the relevance of TP and its potential to predict benefit from postoperative radiation therapy (PORT). METHODS AND MATERIALS: RNA sequencing was successfully performed on 285 samples. TP was inferred using the ESTIMATE algorithm. Associations with overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier and multivariable Cox models. RESULTS: Among 285 patients with resected stage IIIA-N2 non-small cell lung cancer, 144 received PORT. The median age was 61 years, 31% were women, and 80% had nonsquamous histology. Baseline characteristics were well balanced between arms. The median TP was 0.64 (range, 0.41-0.92) and was slightly higher in the PORT arm (0.65 vs 0.63; P = .006). TP correlated with H&E pathologist-estimated cellularity (r = 0.23, P < .001), was higher in squamous tumors (0.68 vs 0.63, P < .001), and increased with necrosis (r = 0.31, P < 10-6). Transcriptomic analysis confirmed associations with proliferation-related pathways and reduced hypoxia signatures (false discovery rate < 0.001). TP inversely correlated with T-cell immune infiltration by immunohistochemistry (CD3⁺ r = -0.52; CD8⁺ r = -0.45). High-TP was associated with worse OS (48.5 vs 106.5 months, P < .001) and DFS (18.4 vs 48.0 months, P = .017). A TP × PORT interaction was observed for OS (P = .049) and a trend for DFS (P = .07). CONCLUSIONS: TP reflects proliferative and tumor microenvironment features; a lower TP is independently associated with improved prognosis in resected stage IIIA-N2 non-small cell lung cancer. PORT may be more effective in tumors with lower TP; however, this finding is exploratory and requires independent validation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zrafi WS, Albarrán-Artahona V, Dall'Olio FG, et al. Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41833910. doi:10.1016/j.ijrobp.2026.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。